Ainos Secures $2.1 Million Order With ASE for First Deployment of AI Nose in Semiconductor Manufacturing Setting
Ainos (NASDAQ:AIMD) has secured a significant $2.1 million three-year subscription order with ASE Technology Holding Co. for deploying its AI Nose platform in semiconductor manufacturing. The agreement involves installing 1,400 AI Nose units across three major manufacturing sites in Taiwan through their SmellTech-as-a-Service model.
This marks Ainos' first revenue-generating industrial deployment, following its initial success in the senior care sector in Q1 2025. The company is expanding with pilot deployments at seven sites in Japan through robotics partner ugo, Inc., and advancing multi-site rollouts with Kenmec and Solomon in Taiwan.
The global e-Nose market is projected to grow from $29.8 billion in 2025 to $76.5 billion by 2032. Ainos' proprietary smell language model (SLM) aims to digitize scent into machine-readable Smell ID data, positioning AI Nose as a trainable AI platform for complex olfactory signals.
Ainos (NASDAQ:AIMD) ha ottenuto un importante ordine di abbonamento triennale da 2,1 milioni di dollari con ASE Technology Holding Co. per l'implementazione della sua piattaforma AI Nose nella produzione di semiconduttori. L'accordo prevede l'installazione di 1.400 unit脿 AI Nose in tre principali siti produttivi a Taiwan tramite il modello SmellTech-as-a-Service.
Questo rappresenta il primo deployment industriale a generare ricavi per Ainos, dopo il successo iniziale nel settore dell'assistenza agli anziani nel primo trimestre del 2025. L'azienda sta espandendo con implementazioni pilota in sette siti in Giappone tramite il partner robotico ugo, Inc., e sta proseguendo con rollout multi-sito con Kenmec e Solomon a Taiwan.
Il mercato globale degli e-Nose 猫 previsto crescere da 29,8 miliardi di dollari nel 2025 a 76,5 miliardi entro il 2032. Il modello proprietario di linguaggio degli odori (SLM) di Ainos punta a digitalizzare gli odori in dati Smell ID leggibili dalle macchine, posizionando AI Nose come una piattaforma AI addestrabile per segnali olfattivi complessi.
Ainos (NASDAQ:AIMD) ha asegurado un significativo pedido de suscripci贸n por tres a帽os y 2,1 millones de d贸lares con ASE Technology Holding Co. para desplegar su plataforma AI Nose en la fabricaci贸n de semiconductores. El acuerdo incluye la instalaci贸n de 1.400 unidades AI Nose en tres importantes sitios de producci贸n en Taiw谩n mediante su modelo SmellTech-as-a-Service.
Este es el primer despliegue industrial que genera ingresos para Ainos, tras su 茅xito inicial en el sector de cuidado de personas mayores en el primer trimestre de 2025. La compa帽铆a se est谩 expandiendo con despliegues piloto en siete sitios en Jap贸n a trav茅s de su socio rob贸tico ugo, Inc., y avanzando en despliegues multisite con Kenmec y Solomon en Taiw谩n.
Se proyecta que el mercado global de e-Nose crecer谩 de
Ainos (NASDAQ:AIMD)電� 氚橂弰觳� 鞝滌“鞐� AI Nose 頂岆灚韽检潉 氚办箻頃橁赴 鞙勴暣 ASE Technology Holding Co.鞕� 2.1氚彪 雼煬 攴滊鞚� 3雲� 甑弲 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. 鞚� 瓿勳暯鞚� 雽�毵岇潣 欤检殧 鞝滌“ 順勳灔 3瓿踌棎 1,400雽�鞚� AI Nose 鞛レ箻毳� SmellTech-as-a-Service 氇嵏鞚� 韱淀暣 靹れ箻頃橂姅 雮挫毄鞚� 韽暔頃╇媹雼�.
鞚措姅 2025雲� 1攵勱赴 雲胳澑 旒�鞏� 攵勳暭鞐愳劀鞚� 齑堦赴 靹标车鞐� 鞚挫柎 Ainos鞚� 觳� 靾橃澋 彀届稖 靷办梾 氚办箻鞛呺媹雼�. 須岇偓電� 搿滊磭 韺岉姼雱� ugo, Inc.鞕� 頃粯 鞚茧掣 雮� 7臧� 靷澊韸�鞐愳劀 韺岇澕霟� 氚办箻毳� 頇曤寑頃橁碃 鞛堨溂氅�, 雽�毵岇棎靹� Kenmec 氚� Solomon瓿� 雼れ 靷澊韸� 搿れ晞鞗冹潉 歆勴枆 欷戩瀰雼堧嫟.
旮�搿滊矊 鞝勳瀽 旖�(e-Nose) 鞁滌灔鞚� 2025雲� 298鞏� 雼煬鞐愳劀 2032雲� 765鞏� 雼煬搿� 靹膘灔頃� 瓴冹溂搿� 鞓堨儊霅╇媹雼�. Ainos鞚� 霃呾瀽鞝侅澑 雰勳儓 鞏胳柎 氇嵏(SLM)鞚� 雰勳儓毳� 旮瓣硠臧� 鞚届潉 靾� 鞛堧姅 Smell ID 雿办澊韯半 霐旍韯疙檾頃橃棳 AI Nose毳� 氤奠灐頃� 頉勱皝 鞁犿樃鞐� 雽�鞚� 臧�電ロ暅 頃欖姷順� AI 頂岆灚韽检溂搿� 鞛愲Μ毵り箑頃橁碃鞛� 頃╇媹雼�.
Ainos (NASDAQ:AIMD) a d茅croch茅 une importante commande d'abonnement de 2,1 millions de dollars sur trois ans aupr猫s d'ASE Technology Holding Co. pour d茅ployer sa plateforme AI Nose dans la fabrication de semi-conducteurs. L'accord pr茅voit l'installation de 1 400 unit茅s AI Nose sur trois principaux sites de production 脿 Ta茂wan via leur mod猫le SmellTech-as-a-Service.
Cela marque le premier d茅ploiement industriel g茅n茅rant des revenus pour Ainos, apr猫s son succ猫s initial dans le secteur des soins aux personnes 芒g茅es au premier trimestre 2025. L'entreprise se d茅veloppe avec des d茅ploiements pilotes sur sept sites au Japon via son partenaire robotique ugo, Inc., et avance dans les d茅ploiements multi-sites avec Kenmec et Solomon 脿 Ta茂wan.
Le march茅 mondial des e-Nose devrait passer de 29,8 milliards de dollars en 2025 脿 76,5 milliards d'ici 2032. Le mod猫le propri茅taire de langage olfactif (SLM) d'Ainos vise 脿 num茅riser les odeurs en donn茅es Smell ID lisibles par machine, positionnant AI Nose comme une plateforme d'IA entra卯nable pour des signaux olfactifs complexes.
Ainos (NASDAQ:AIMD) hat einen bedeutenden Abonnementauftrag 眉ber drei Jahre im Wert von 2,1 Millionen US-Dollar mit ASE Technology Holding Co. gesichert, um seine AI Nose-Plattform in der Halbleiterfertigung einzusetzen. Die Vereinbarung umfasst die Installation von 1.400 AI Nose-Einheiten an drei gro脽en Fertigungsstandorten in Taiwan 眉ber ihr SmellTech-as-a-Service-Modell.
Dies markiert den ersten umsatzgenerierenden industriellen Einsatz von Ainos nach dem ersten Erfolg im Seniorenbetreuungssektor im ersten Quartal 2025. Das Unternehmen expandiert mit Pilotprojekten an sieben Standorten in Japan 眉ber den Robotikpartner ugo, Inc. und treibt Multi-Standort-Rollouts mit Kenmec und Solomon in Taiwan voran.
Der globale e-Nose-Markt wird voraussichtlich von 29,8 Milliarden US-Dollar im Jahr 2025 auf 76,5 Milliarden US-Dollar bis 2032 wachsen. Ainos鈥� propriet盲res Geruchssprachmodell (SLM) zielt darauf ab, D眉fte in maschinenlesbare Smell ID-Daten zu digitalisieren und positioniert AI Nose als trainierbare KI-Plattform f眉r komplexe olfaktorische Signale.
- Secured significant $2.1 million three-year subscription order with ASE Technology
- Large-scale deployment of 1,400 AI Nose units across three major manufacturing sites
- Expanding market presence with seven pilot sites in Japan and multiple sites in Taiwan
- Operating in a rapidly growing market projected to reach $76.5 billion by 2032
- Successfully transitioning from strategic partnerships to revenue-generating commercial deployments
- Early stage of commercial deployment with limited revenue history
- Heavy dependence on Asian market for initial deployments
- Requires continuous data acquisition to improve model performance
Insights
Ainos secures first major industrial revenue for AI Nose technology with $2.1M ASE deal, validating their smell-based AI platform.
Ainos has achieved a significant commercial milestone with a
The technology value proposition is compelling. Ainos is positioning their offering not merely as scent sensors but as a comprehensive SmellTech-as-a-Service platform powered by their proprietary smell language model (SLM). In semiconductor manufacturing, where process stability and equipment reliability are critical, AI Nose aims to provide predictive insights through olfactory data that traditional sensors miss.
This deal validates Ainos' business model in a high-value industrial setting. The three-year subscription structure suggests a recurring revenue stream rather than one-time hardware sales, aligning with modern SaaS economics. For context, the global e-Nose market is projected to grow from
Beyond ASE, Ainos is executing a deliberate multi-market deployment strategy with additional rollouts in Japan (via robotics partner ugo) and Taiwan (with Kenmec and Solomon). This geographical diversification across manufacturing environments creates a data acquisition flywheel that could strengthen their AI models鈥攁 classic network effect that potentially builds defensibility.
The framing of scent as "AI's next token" positions Ainos at the intersection of two powerful technology trends: specialized AI sensing and industrial IoT. If successful, they're establishing first-mover advantage in what they characterize as an underdeveloped frontier in artificial intelligence.
First Revenue-Generating Milestone for AI Nose Smell Language Model in High-Value Industrial Applications
Ainos Building Commercial Momentum with Multi-Site Deployments Underway in Japan and Taiwan
SAN DIEGO, CALIFORNIA / / August 6, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced it has secured a three-year subscription-based order valued at
Under the agreement, Ainos will deploy 1,400 AI Nose units across ASEH's three major manufacturing sites in Taiwan-Kaohsiung, Zhongli, and SPIL. Through this rollout, Ainos will launch its SmellTech-as-a-Service model to enhance ASEH's smart manufacturing initiatives, enabling AI-powered scent intelligence designed to improve process stability, support predictive maintenance, and increase operational safety.
This milestone marks the first revenue-generating order for AI Nose in the industrial market. It is the second commercial success, following its first revenue in the senior care sector during 1Q 2025. Together, these developments validate Ainos' strategic focus on labor-constrained, sensor-intensive environments where traditional sensing modalities fall short.
"We're executing with speed and precision," said Eddy Tsai, Chairman and CEO of Ainos. "This initial deployment proves AI Nose's real-world value-and it's just the beginning. We're expanding SmellTech into high-impact industrial applications. Next, we'll begin pilot deployments at seven sites in Japan with our robotics partner ugo, Inc., strengthening our presence in that market. In Taiwan, we're advancing multi-site rollouts with Kenmec, and Solomon. We're actively delivering on our global commercialization roadmap, and the second half of 2025 will be a defining chapter as we scale across Asia."
The agreement follows Ainos' previous announcement of an expanded strategic partnership with ASEH. Today's milestone represents the transition of that partnership into commercial deployment, reinforcing customer confidence and platform maturity.
Ainos identified the ASEH deployment as a core deliverable in its 90-day execution plan, outlined in its previous corporate update. The plan focuses on converting strategic partnerships into active deployments, generating recurring revenue, and accelerating data acquisition to improve model performance across real-world environments. Deployments in Japan and Taiwan support this data flywheel, strengthening Ainos' AI model training pipeline for global applications.
The global electronic nose (e-Nose) market is projected to grow from
"Scent is emerging as AI's next token-just as words power LLMs and pixels fuel vision AI, scent data will define the next wave of machine perception," Tsai added. "With AI Nose, we're understanding, classifying, and acting on olfactory information."
This agreement further strengthens Ainos' footprint in Asia's advanced manufacturing base and reinforces its position as a first mover in SmellTech-an underdeveloped but high-impact frontier in artificial intelligence. Headquartered in the U.S. and working alongside partners across Taiwan, Japan, and the global industrial ecosystem, Ainos is accelerating the commercialization of AI-powered olfaction.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.
About Ainos, Inc.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA庐, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit . Follow Ainos on X, formerly known as Twitter, () and to stay up-to-date.
About ASE Technology Holding Co., Ltd.
ASE Technology Holding is the leading provider of semiconductor manufacturing services in assembly and test. ASEH develops and offers complete turnkey solutions covering front-end engineering test, wafer probing and final test, as well as packaging, materials and electronic manufacturing services through USI with superior technologies, breakthrough innovations, and advanced development programs. With advanced technological capabilities and a global presence spanning Taiwan, China, South Korea, Japan, Singapore, Malaysia, Philippines, Vietnam, Mexico, and Tunisia as well as the United States and Europe, ASEH has established a reputation for reliable, high quality products and services. For more information, please visit .
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
SOURCE: Ainos, Inc.
View the original on ACCESS Newswire
FAQ
What is the value of Ainos (AIMD) contract with ASE Technology?
How many AI Nose units will Ainos deploy for ASE Technology?
What is the projected growth of the global e-Nose market by 2032?
Where is Ainos expanding its AI Nose deployment beyond Taiwan?
What was Ainos first commercial success with AI Nose before ASE?
